Cortagen

Bioregulators Research compound (not approved for human use)

Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro) · also known as AEDP, Ala-Glu-Asp-Pro

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Cortagen is associated in the originating literature with cerebral cortex function and with differentiation of nervous tissue. Evidence comes mainly from rat studies and cell work by one group; no controlled human dosing data are available for the vial format.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	1 mg	0.15 mL	15
Standard	2 mg	0.3 mL	30

Frequency: Once daily, subcutaneous (4-week courses, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Proposed to influence gene expression and lower oxidative stress in neural tissue; reported effects in rats include reduced lipid peroxidation products and modulation of IL-2 gene expression in the hypothalamus.

Researched for

Studied in rats with chronic brain ischemia for behavior and oxidative-stress markers.
Examined for effects on lipid peroxidation and antioxidant activity in rat serum and cerebral cortex.
Investigated for modulation of IL-2 gene expression in rat hypothalamic structures.

Notes

Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.

Sources

Last reviewed 2026-10-06.

Pinealon

Synthetic tripeptide bioregulator (Glu-Asp-Arg)

Pinealon is a three-residue peptide (glutamate, aspartate, arginine) developed by the Khavinson group as a brain-oriented bioregulator.

20 mg vial · Once daily, subcutaneous, in 10-20 day courses (community-reported)

Vilon

Synthetic dipeptide bioregulator (Lys-Glu)

Vilon is the two-residue peptide lysine-glutamate (Lys-Glu), developed by the Khavinson group as a thymus-related immune bioregulator.

20 mg vial · Once daily for 5 consecutive days, then about 23 days off (community-reported)

Cartalax

Synthetic tripeptide bioregulator (Ala-Glu-Asp)

Cartalax is a three-residue peptide (alanine, glutamate, aspartate) studied by the Khavinson group in connection with cartilage and connective tissue.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)